AMR Bio: Commercial Update We are pleased to provide a commercial update on AMR Bio Limited (AMR Bio), the clinical-stage biotechnology company focused on infection prevention and antimicrobial resistance (AMR). AMR Bio’s lead asset, XF-73, is a Phase 2b first-in-class topical antimicrobial designed to prevent post-surgical infections by rapidly eliminating harmful bacteria prior to surgery. The programme is now advancing […]
By Dr. Ilian Iliev, CEO of EMV Capital PLC Whatever the outcome of the ongoing conflict in the Gulf region, energy prices (oil and gas in particular) are likely to remain elevated for a prolonged period. This will have many political and macroeconomic impacts, which I will leave for others to write about. My focus here is on what we […]
We need a whole stack approach to introduce novel technologies for sustainable AI infrastructure By Dr Ilian Iliev, CEO of EMV Capital PLC The race to dominate in AI is not constrained by capital or talent so much as by electricity. Data-centre energy use is ballooning so quickly that the result is a looming collision between digital ambition and physical […]